Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Elite provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as a Distinguished provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Wyndham Wilson is an Oncologist in Bethesda, Maryland. Dr. Wilson is rated as a Distinguished provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Burkitt Lymphoma.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Advanced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Leukemia, and Splenectomy.

Md Siddiqui is a Hematologist Oncology specialist and a Hematologist in Salisbury, Maryland. Dr. Siddiqui is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Pulmonary Embolism, Inflammatory Breast Cancer, Angiosarcoma, and Childhood Iron Deficiency Anemia. Dr. Siddiqui is currently accepting new patients.

Bruce Cheson is a Hematologist and a Hematologist Oncology provider in Bethesda, Maryland. Dr. Cheson is rated as a Distinguished provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Cheson is currently accepting new patients.

Adrian Wiestner is a Hematologist in Bethesda, Maryland. Dr. Wiestner is rated as a Distinguished provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, and Small Lymphocytic Lymphoma (SLL).

Aaron Rapoport is a Hematologist in Baltimore, Maryland. Dr. Rapoport is rated as a Distinguished provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rapoport is currently accepting new patients.

"Dr. Ari D. Fishman is a hematologist affiliated with Sibley Memorial Hospital, Holy Cross Hospital and George Washington University Hospital, where he serves as an assistant professor of medicine for the School of Medicine. He practices out of Maryland Oncology and Hematology, located in Wheaton, Maryland and Silver Spring, Maryland. Dr. Fishman earned his medical degree from Sackler School of Medicine. He completed a residency in internal medicine at the Beth Israel Medical Center, followed by a fellowship in hematology and oncology at the Montefiore Medical Center. Dr. Fishman previously worked at Washington Oncology Hematology Center, located in Washington, D.C. and Chevy Chase, Maryland. Dr. Fishman has been named a Top Doctor in Hematology and Oncology by Washingtonian Magazine and a Top Doctor by Consumers’ Checkbook magazine. Dr. Fishman is a member of the American College of Physicians and the American Society of Clinical Oncology. Dr. Fishman has contributed to numerous publications. Selected Publications Fishman AD, Hoffman A, Volterra F, Frymus M, Gentilluci M. ""Intracaval and intracardiac metastatic nonseminomatous germ cell tumor: a rare cause of hemolytic anemia and thrombocytopenia."" Cancer Invest. 2002;20(7-8):996-1001.". Dr. Fishman is rated as an Advanced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndrome (MDS), and Childhood Iron Deficiency Anemia.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

Dr. Stefan Loy Zimmerman is a Professor in the Johns Hopkins University School of Medicine in the Departments of Radiology and Medicine (Cardiology). He specializes in cardiothoracic imaging and is the Division Director of Diagnostic Imaging and Director of Cardiac Imaging. He is the program director for the Cardiothoracic Imaging Fellowship in Radiology. Dr. Zimmerman earned his medical degree from the University of Pennsylvania School of Medicine. He completed both a radiology residency and a cardiovascular imaging fellowship at the Hospital of the University of Pennsylvania. His research focuses on the use of CT and MR imaging in the diagnosis and management of cardiovascular diseases. He has particular interest in the use of cardiac imaging for management of arrhythmias, diagnosis and prognosis of arrhythmogenic right and left ventricular cardiomyopathy, and pulmonary hypertension. Dr. Zimmerman is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Paroxysmal Supraventricular Tachycardia (PSVT), Alveolar Soft Part Sarcoma, Liposarcoma, Cardiac Ablation, and Transcatheter Aortic Valve Replacement (TAVR).

Mark Goldstein is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Goldstein is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Childhood Iron Deficiency Anemia, Anal Cancer, Myelodysplastic Syndrome (MDS), and Pleuropulmonary Blastoma.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Dr. Craig received his Bachelor’s degree from the U.S. Naval Academy, followed by medical school at The Uniformed Services University of the Health Sciences. During his career as a Navy radiologist, Dr. Craig served as Radiologic Consultant to the White House and Capitol Physician and as Chairman of Radiology at both Bethesda Naval Hospital and the Department of Radiologic Pathology at the Armed Forces Institute of Pathology where he was also section head of Genito-Urinary Imaging. Dr. Craig specializes in oncologic imaging and abdominal imaging with a focus on the genito-urinary system lecturing both nationally and internationally. He currently serves as Chairman of Radiology at Suburban Hospital, volunteers with the American Board of Radiology and is a journal reviewer for Radiographics. Dr. Craig is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Collapsed Lung, Gallbladder Disease, Pleurisy, and Pleural Effusion.

Edward Lee, M.D. was named one of Baltimore’s “Top Doc’s” by Baltimore Magazine in 2000 and 2002. After receiving additional training in Hematology and Medical Oncology at the University of Maryland in 1984, he remained on faculty until 1997. During his academic career, Dr. Lee was chairman of the training program for five years, started the Bone Marrow Transplant Program at the University of Maryland in 1993, and wrote 50 original articles on leukemia, lymphoma and related diseases. In 1997, Dr. Lee entered private practice as Chief of Hematology and Medical Oncology at Sinai Hospital. Practicing in Columbia since 2001, Dr. Lee treats patients with all forms of cancer, maintaining a particular interest in breast cancer, leukemia, and lymphomas. Learn more at marylandoncology.com. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Polycythemia Vera, Paget Disease of the Breast, Breast Cancer, and Primary Lymphoma of the Brain.

Blanche Mavromatis is an Oncologist in Cumberland, Maryland. Dr. Mavromatis is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome. Dr. Mavromatis is currently accepting new patients.

Learn more at marylandoncology.com. Dr. Sastry is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia.

Dr. Abhishek Srinivas received his medical degree from the Johns Hopkins School of Medicine in 2006. He completed his diagnostic radiology residency at the Montefiore Medical Center of the Albert Einstein College of Medicine in New York in 2011. This was followed by a fellowship in Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine in 2012. Prior to joining Johns Hopkins as faculty, Dr. Srinivas established an interventional oncology practice serving much of central New Jersey, and a local hub for patients affiliated with Hahnemann University Hospital’s liver transplant program in Philadelphia. During this time, Dr. Srinivas was also part of the neuroradiology team for the hospital’s stroke center. His primary areas of expertise include interventional oncology (liver, kidney and bone cancers), vascular disease (deep vein thrombosis, pulmonary embolism, aneurysm treatment), uterine fibroid embolization, spine interventions, and advanced biliary interventions. Other interests include novel device evaluation and development. Videos Abhishek Srinivas, M.D. Selected Publications Chang SW, Srinivas A, Murphy KP. Chapter 5: Endovascular Management of a Patient After SAH. Bhardwaj A, Alkayed NJ, Kirsch JR, et al. Acute Stroke: Bench to Bedside. Chapter 5, 53 – 61. New York: Marcel Dekker. Copyright 2007, informa Healthcare USA inc. Farinhas, J, Srinivas A, Gulko E, Bello J. Chapter 4: Imaging of the Spine and Spinal Cord. Kirshblum S, Campagnolo D, DeLisa JA, Spinal Cord Medicine 2nd Edition. Lippincott, Williams, & Wilkins (Copyright 2011) Gailloud P, Srinivas A, Chang SW, Murphy KP. Morgan RH. Percutaneous Vertebroplasty in a Sitting Patient. Journal of Vascular and Interventional Radiology. 2005 Nov; 16(11):1558-9 Mahadevia AA, Weiland D, Kvamme P, Murphy KP, Srinivas A, Wyse G. Polymethylmethacrylate contact dermatitis after vertebroplasty. Journal of Vascular and Interventional Radiology 2007 Apr;18(4):585 Srinivas A, Chang SW, Gailloud P. Chapter 33: Diagnosis and Treatment of Cerebral Arteriovenous Malformations. Bhardwaj A, Alkayed NJ, Kirsch JR, et al. Acute Stroke: Bench to Bedside. Chapter 33, 397 – 404. New York: Marcel Dekker. Copyright 2007, informa Healthcare USA inc. Dr. Srinivas is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Bile Duct Obstruction, Ascites, Jaundice, Liver Embolization, and Bone Graft.

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy.